QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
Log in
NASDAQ:IMTX

Immatics Stock Forecast, Price & News

$10.26
+0.01 (+0.10 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.24
Now: $10.26
$10.45
50-Day Range
$9.90
MA: $10.76
$12.05
52-Week Range
$8.66
Now: $10.26
$17.48
Volume55,806 shs
Average Volume189,464 shs
Market Capitalization$184.37 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.09
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tübingen, Germany.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Holding & other investment offices
Sub-IndustryN/A
Current SymbolNASDAQ:IMTX
CUSIPN/A
CIKN/A
Phone212-284-2300
Employees220

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$0.15 per share
Book Value$0.28 per share

Profitability

Net Income$2.58 million

Miscellaneous

Market Cap$184.37 million
Next Earnings Date11/25/2020 (Estimated)
OptionableNot Optionable
$10.26
+0.01 (+0.10 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immatics (NASDAQ:IMTX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Immatics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Immatics
.

What stocks does MarketBeat like better than Immatics?

Wall Street analysts have given Immatics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immatics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Immatics' next earnings date?

Immatics is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020.
View our earnings forecast for Immatics
.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) released its earnings results on Thursday, September, 3rd. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.20. The business earned $7.70 million during the quarter, compared to analysts' expectations of $8.49 million.
View Immatics' earnings history
.

What price target have analysts set for IMTX?

5 brokers have issued 1 year price objectives for Immatics' shares. Their forecasts range from $13.00 to $28.00. On average, they expect Immatics' stock price to reach $17.80 in the next year. This suggests a possible upside of 73.5% from the stock's current price.
View analysts' price targets for Immatics
.

Who are some of Immatics' key competitors?

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Datadog (DDOG), Forte Biosciences (FBRX), Galiano Gold (GAU), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

Who are Immatics' key executives?

Immatics' management team includes the following people:
  • Dr. Harpreet Singh, CEO, MD & Member of Management Board (Age 46)
  • Dr. Hans-George Rammensee, Co-Founder, Head of the Scientific Advisory Board
  • Dr. Toni Weinschenk Ph.D., Co-Founder & Chief Innovation Officer (Age 47)
  • Mr. Arnd Christ, Chief Financial Officer (Age 54)
  • Ms. Jessica Mosby Ed.D., Sr. Director HR & Operations
  • Mr. Steffen Walter Ph.D., Chief Technology Officer (Age 44)
  • Mr. Edward A. Sturchio, Gen. Counsel
  • Ms. Anja Heuer B.Sc., Sr. Mang. of Corp. Communications
  • Dr. Carsten Reinhardt, Chief Devel. Officer (Age 53)
  • Dr. Rainer Kramer, Chief Bus. Officer (Age 56)

What is Immatics' stock symbol?

Immatics trades on the NASDAQ under the ticker symbol "IMTX."

Who are Immatics' major shareholders?

Immatics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (14.59%), Perceptive Advisors LLC (13.91%), Federated Hermes Inc. (9.77%), Sphera Funds Management LTD. (4.45%), University of Texas Texas AM Investment Managment Co. (3.88%) and Sofinnova Investments Inc. (1.81%).

Which institutional investors are buying Immatics stock?

IMTX stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Perceptive Advisors LLC, Federated Hermes Inc., Sphera Funds Management LTD., University of Texas Texas AM Investment Managment Co., Sofinnova Investments Inc., Platinum Investment Management Ltd., and California Public Employees Retirement System.

How do I buy shares of Immatics?

Shares of IMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immatics' stock price today?

One share of IMTX stock can currently be purchased for approximately $10.26.

How big of a company is Immatics?

Immatics has a market capitalization of $184.37 million. Immatics employs 220 workers across the globe.

What is Immatics' official website?

The official website for Immatics is www.immatics.com.

How can I contact Immatics?

Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The company can be reached via phone at 212-284-2300.

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.